Notable subgroups that did not benefit with pola-R-CHP included younger (3⁄460) patients, patients with the germinal-center (GC) B-cell–like subtype of DLBCL, patients who had bulky disease, and patients who had lower IPI scores (IPI 2 vs 3-5). The gene discussed is POLA1; the disease is diffuse large B-cell lymphoma.